Christoph is currently the CSO of Curie.Bio. Prior to co-founding Curie.Bio, he was a partner at Third Rock Ventures where he has been instrumental in founding and launching several companies including Relay Therapeutics, Thrive Earlier Detection, Celsius Therapeutics, and MOMA Therapeutics. Christoph has contributed to the discovery and development of ten FDA-approved cancer medicines.
Prior to joining Third Rock, Christoph was CSO and chief drug hunter at Blueprint Medicines, global head of oncology drug discovery at Sanofi, and senior unit head of oncology discovery at Novartis. Prior to Novartis, Christoph was an associate professor at the Johns Hopkins University School of Medicine where he was involved in the identification of several cancer driver genes including PIK3CA and BRAF. As part of his research, Christoph discovered that all cancers are genetically unstable, which explains the molecular heterogeneity of cancer and why cancers develop resistance to cancer drugs. He has authored more than 100 scientific articles published in top-tier scientific journals, including Cell, Nature and Science.
Christoph studied human genetics in Salzburg, Austria and got his PhD in biology from the University of Heidelberg in Germany. He received his MBA with a focus on medical services management from the Johns Hopkins Carey Business School. Christoph has received numerous awards, including the Novartis Oncology President’s Award for Top Innovator. He has been elected to membership in the Johns Hopkins Society of Scholars. Christoph is a strong and outspoken advocate of patients’ rights and is featured in the New York Times bestseller and HBO movie The Immortal Life of Henrietta Lacks. He coached the Johns Hopkins Women’s soccer team for several years and was director of coaching at the Baltimore Bays Premier Soccer Club.
Dr. Burris serves as president and chief medical officer of
Sarah Cannon, as well as the executive director, drug development for the
research institute. He is an associate of Tennessee Oncology, PLLC, where he
practices medical oncology.
Dr. Burris’ clinical research career has focused on the
development of new cancer agents with an emphasis on first in human therapies,
having led the trials of many novel antibodies, small molecules, and
chemotherapies now FDA approved, including ado-trastuzumab emtansine,
everolimus, and gemcitabine. In 1997, he established in Nashville the first
community based early phase drug development program, which grew into the Sarah
Cannon Research Institute. He has authored over 400 publications and 700
abstracts. Sarah Cannon has now dosed over 350 first in human anticancer
therapies and enrolls more than 3000 patients per year into clinical trials.
Dr Burris was recently elected president of the American
Society of Clinical Oncology (ASCO), a professional society representing over
40,000 cancer physicians and researchers globally. He also currently serves on
the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris
was selected by his peers as a Giant of Cancer Care for his achievements in
Dr. Burris completed his undergraduate education
at the United States Military Academy at West Point, his medical degree at the
University of South Alabama, and his internal medicine residency and oncology
fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he
also served as the Director of Clinical Research at The Institute for Drug
Development of the Cancer Therapy and Research Center and The University of
Texas Health Science Center. He attained the rank of lieutenant colonel in the
US Army, and among his decorations, he was awarded a Meritorious Service Medal
with oak leaf cluster for his service in Operation Joint Endeavor.
Dr. Peter A Kiener currently is a member of the Scientific
Advisory Board of Mersana. He is currently the Chief Executive Officer of
Cereius Inc. Prior to joining Cereius,
he served as CSO and Head of Research and Development at Sucampo Pharma Inc, a
fully integrated Biopharma company, and CSO of of Ambrx Inc., a clinical-stage
biopharmaceutical company focused on the development of antibody-drug
From 2009 to 2013, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener previously worked on biologics for Bristol-Myers Squibb from 1983 to 2001. Dr. Kiener began his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983, and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. Dr. Kiener currently serves as Chairman of the Board of Managers of Resolve LLC, and is a member of the Board of Directors of Cue Pharma LLC and Tetragenetics Inc.
He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.
Prof. Dane Wittrup attended the University of New Mexico as an undergraduate, graduating Summa Cum Laude with a Bachelor’s in Chemical Engineering in June, 1984. Wittrup went on to attend the California Institute of Technology in Pasadena, where he worked with Prof. James Bailey on flow cytometry and segregated modeling of recombinant populations of Saccharomyces cerevisiae.
After obtaining his Ph.D. in Chemical Engineering with a minor in Biology in 1988, he spent a brief time working at Amgen before becoming an Assistant Professor of Chemical Engineering at the University of Illinois at Urbana-Champaign in 1989. He moved to the Massachusetts Institute of Technology in September of 1999, where he is now the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, in addition to working with the Koch Institute as the Associate Director for Engineering.